ArticleJHEP reports : innovation in hepatology2026
Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background & Aims: Sorafenib has been a cornerstone of hepatocellular carcinoma (HCC) therapy; however, its efficacy is limited, and identifying patients who will benefit from sorafenib is challenging. We aimed to identify predictive biomarkers of sorafenib benefit in patients with HCC. Methods: Gene expression data from 33 HCC tumors treated with sorafenib were analyzed to construct a prediction model aimed at identifying patients with greater benefit from sorafenib treatment. The robustness of the predictor was validated using gene expression data from two phase III clinical trials, IMbrave150 and STORM. Results: The analysis of transcriptome data revealed a 50-gene signature, the KUSS50 (Korea University Sorafenib Signature with 50 genes), that exhibited high predictive power in identifying patients who benefited from sorafenib treatment in a training cohort. Validation in two independent cohorts - IMbrave150 (n = 48) and BIOSTORM (n = 67) -demonstrated high specificity for predicting sorafenib benefit (AUC: 87.1%, Conclusions: The KUSS50 is a clinically actionable biomarker that may optimize patient selection for sorafenib treatment in HCC, potentially improving outcomes. Further exploration of the underlying biology of KUSS50-defined subtypes - particularly the role of ferroptosis in sorafenib sensitivity - may yield additional therapeutic insights. Impact and implications: This study identifies the KUSS50, a novel 50-gene signature, as a predictive biomarker for identifying patients with hepatocellular carcinoma (HCC) who are likely to benefit from sorafenib treatment. The findings have significant implications for the clinical management of HCC, particularly in optimizing treatment strategies and enhancing patient outcomes. The ability to predict the benefit of sorafenib treatment with high specificity allows for more personalized therapy, reducing unnecessary exposure to ineffective treatments. This approach can be directly applied by clinicians to improve treatment selection, ultimately leading to better patient outcomes. Additionally, understanding the molecular mechanisms underlying the KUSS50-defined subtypes may pave the way for new therapeutic strategies and interventions aimed at improving the efficacy of sorafenib and other treatments in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.